Drug intelligence / Profile preview

predever

Development stage: Unknown
Modality: Small Molecules

Overview

Predever is a combination therapy consisting of prednisone and everolimus, investigated for the treatment of newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD). Prednisone is a synthetic corticosteroid that acts as an immunosuppressant and anti-inflammatory agent by binding to glucocorticoid receptors. Everolimus is an mTOR inhibitor, also possessing immunosuppressive properties by blocking the activity of the mammalian target of rapamycin (mTOR) pathway. This combination aims to improve long-term treatment success in cGVHD patients.

Other names: PredEver first

Targets

FKBP1AGR (Glucocorticoid receptor)Mechanistic target of rapamycin complex 1

Beyond the preview

Go deeper on predever.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on predever.

Explore the full profile